SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-19-000032
Filing Date
2019-05-08
Accepted
2019-05-08 16:36:13
Documents
62
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q Q1 2019 dnli-20190331.htm   iXBRL 10-Q 1854161
2 EXHIBIT 31.1 exhibit311q12019.htm EX-31.1 12568
3 EXHIBIT 31.2 exhibit312q12019.htm EX-31.2 12104
4 EXHIBIT 32.1 exhibit321q12019.htm EX-32.1 7983
5 EXHIBIT 32.2 exhibit322q12019.htm EX-32.2 8121
  Complete submission text file 0001714899-19-000032.txt   7349580

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20190331.xsd EX-101.SCH 48791
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20190331_cal.xml EX-101.CAL 67197
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20190331_def.xml EX-101.DEF 255165
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20190331_lab.xml EX-101.LAB 596475
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20190331_pre.xml EX-101.PRE 381110
11 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20190331_htm.xml XML 1264240
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 19807192
SIC: 2836 Biological Products, (No Diagnostic Substances)